Market Overview

UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation

Share:
Related IMGN
ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference
Buy ImmunoGen On Transformational Products, Jefferies Says

Credit Suisse initiated coverage on Immunogen (NASDAQ: IMGN) with a Neutral rating and a $12 price target.

Credit Suisse noted, "We like IMGN for its expected steady cash flow from T-DM1 royalties, its antibody-drug conjugation (ADC) technology, and potential upside from a deep pipeline. However, upside to valuation requires additional drivers for which visibility is currently low."

Immunogen closed at $11.65 on Monday.

Latest Ratings for IMGN

DateFirmActionFromTo
Nov 2015JefferiesAssumesHoldBuy
Oct 2015Leerink SwannMaintainsMarket Perform
Sep 2015Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IMGN)

Get Benzinga's Newsletters